Newly developed direct-acting anti-viral drugs act as a major breakthrough in the area of HCV therapeutics. Accumulating evidence suggest that more than 99% patients achieve sustained virological response after receiving sofosbuvir-based therapy. However, we observed the first case of DAA treatment failure in HCV patient who was co-infected with H. Pylori.
Keywords: DAA drugs, HCV, H. pylori, sofosbuvir, relapse.
